[{"id":"76342840-6206-4b74-a0cb-9378bde5b3a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469891","created_at":"2026-03-28T01:43:33.576Z","updated_at":"2026-03-28T01:43:33.576Z","phase":"Phase 1","brief_title":"A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms","source_id_and_acronym":"NCT07469891","lead_sponsor":"Prelude Therapeutics","biomarkers":" JAK2","pipe":"","alterations":" ","tags":["JAK2"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2026-03-13"},{"id":"6ad48fdc-0f2c-4ee1-985e-f1329da636f0","acronym":"SYTHROM","url":"https://clinicaltrials.gov/study/NCT04539678","created_at":"2021-01-21T20:53:00.583Z","updated_at":"2025-02-25T13:40:13.722Z","phase":"","brief_title":"SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications","source_id_and_acronym":"NCT04539678 - SYTHROM","lead_sponsor":"Nantes University Hospital","biomarkers":" CALR","pipe":"","alterations":" ","tags":["CALR"],"overall_status":"Completed","enrollment":" Enrollment 253","initiation":"Initiation: 05/21/2019","start_date":" 05/21/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-02-21"},{"id":"0841b3a2-d056-4bdc-8db6-285dc71005a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02506933","created_at":"2021-01-18T12:06:04.560Z","updated_at":"2025-02-25T14:06:51.914Z","phase":"Phase 2","brief_title":"Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant","source_id_and_acronym":"NCT02506933","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Triplex (CMV-MVA vaccine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 11/05/2015","start_date":" 11/05/2015","primary_txt":" Primary completion: 01/25/2018","primary_completion_date":" 01/25/2018","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-17"},{"id":"5202b47d-cbbb-4824-a53c-3a13ffa0fe0a","acronym":"LIMBER","url":"https://clinicaltrials.gov/study/NCT05936359","created_at":"2023-07-07T14:09:44.600Z","updated_at":"2025-02-25T14:42:12.068Z","phase":"Phase 1","brief_title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","source_id_and_acronym":"NCT05936359 - LIMBER","lead_sponsor":"Incyte Corporation","biomarkers":" CALR","pipe":"","alterations":" ","tags":["CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2025-02-14"},{"id":"70692651-6672-45ae-886f-cba93081de75","acronym":"LIMBER","url":"https://clinicaltrials.gov/study/NCT06034002","created_at":"2023-09-13T15:10:28.189Z","updated_at":"2025-02-25T14:42:20.629Z","phase":"Phase 1","brief_title":"A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms","source_id_and_acronym":"NCT06034002 - LIMBER","lead_sponsor":"Incyte Corporation","biomarkers":" CALR","pipe":"","alterations":" ","tags":["CALR"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/04/2023","start_date":" 12/04/2023","primary_txt":" Primary completion: 10/29/2028","primary_completion_date":" 10/29/2028","study_txt":" Completion: 10/29/2028","study_completion_date":" 10/29/2028","last_update_posted":"2025-02-14"},{"id":"002fe85e-b3d8-4f4c-9679-0e7ceacd8f48","acronym":"MCC-20963","url":"https://clinicaltrials.gov/study/NCT05177211","created_at":"2022-01-04T13:53:44.017Z","updated_at":"2025-02-25T14:16:34.238Z","phase":"Phase 2","brief_title":"Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)","source_id_and_acronym":"NCT05177211 - MCC-20963","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inrebic (fedratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-13"},{"id":"a688087c-68be-4853-9780-49620057e35d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04517851","created_at":"2021-01-18T21:38:49.784Z","updated_at":"2025-02-25T15:26:29.899Z","phase":"Phase 2","brief_title":"Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis","source_id_and_acronym":"NCT04517851","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" JAK2 • IL1R1 • SLAMF7","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • IL1R1 • SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Empliciti (elotuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/10/2021","start_date":" 02/10/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-10"},{"id":"161e5bfa-d426-464a-9703-09d1a3988f05","acronym":"","url":"https://clinicaltrials.gov/study/NCT05600894","created_at":"2022-11-05T15:14:14.733Z","updated_at":"2025-02-25T16:39:25.353Z","phase":"Phase 2","brief_title":"Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm","source_id_and_acronym":"NCT05600894","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 06/27/2023","start_date":" 06/27/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-07"},{"id":"930271d4-4c89-4b12-9340-38647392d747","acronym":"","url":"https://clinicaltrials.gov/study/NCT05732961","created_at":"2023-02-17T15:00:52.691Z","updated_at":"2025-02-25T14:17:40.080Z","phase":"Phase 2","brief_title":"Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms","source_id_and_acronym":"NCT05732961","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/20/2025","primary_completion_date":" 06/20/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-07"},{"id":"ee309a82-4f0b-426f-a0b1-deeeabf2fd59","acronym":"","url":"https://clinicaltrials.gov/study/NCT04802161","created_at":"2021-03-17T15:57:34.517Z","updated_at":"2025-02-25T16:32:23.537Z","phase":"Phase 2","brief_title":"Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes","source_id_and_acronym":"NCT04802161","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2","pipe":" | ","alterations":" Chr del(11q)","tags":["RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation) • pomalidomide • thalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"7f3a4417-d9e1-41f2-85e6-183300a2b151","acronym":"NCI-2017-01311","url":"https://clinicaltrials.gov/study/NCT03246906","created_at":"2021-01-18T16:02:34.370Z","updated_at":"2025-02-25T16:44:11.978Z","phase":"Phase 2","brief_title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","source_id_and_acronym":"NCT03246906 - NCI-2017-01311","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/11/2017","start_date":" 09/11/2017","primary_txt":" Primary completion: 05/03/2025","primary_completion_date":" 05/03/2025","study_txt":" Completion: 05/03/2025","study_completion_date":" 05/03/2025","last_update_posted":"2025-02-05"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"625a8643-bad7-473d-8b71-3b4bd3eac313","acronym":"MPN-RC 119","url":"https://clinicaltrials.gov/study/NCT04281498","created_at":"2021-01-18T20:47:14.678Z","updated_at":"2025-02-25T14:29:04.725Z","phase":"Phase 2","brief_title":"Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation","source_id_and_acronym":"NCT04281498 - MPN-RC 119","lead_sponsor":"John Mascarenhas","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2025-02-04"},{"id":"641e6271-0e87-4441-87f5-e22bb1c67e28","acronym":"IFN\u0026SMP","url":"https://clinicaltrials.gov/study/NCT05850273","created_at":"2023-05-09T14:04:26.422Z","updated_at":"2025-02-25T16:54:57.682Z","phase":"","brief_title":"Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms","source_id_and_acronym":"NCT05850273 - IFN\u0026SMP","lead_sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","biomarkers":" CD38 • CD34 • THY1","pipe":"","alterations":" ","tags":["CD38 • CD34 • THY1"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 03/16/2028","primary_completion_date":" 03/16/2028","study_txt":" Completion: 03/16/2033","study_completion_date":" 03/16/2033","last_update_posted":"2025-02-04"},{"id":"1b4e994d-52e1-4f2a-9230-cf391cb47aea","acronym":"NCI-2023-03572","url":"https://clinicaltrials.gov/study/NCT06034470","created_at":"2023-09-13T14:09:48.343Z","updated_at":"2025-02-25T17:02:50.246Z","phase":"Phase 1","brief_title":"Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms","source_id_and_acronym":"NCT06034470 - NCI-2023-03572","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" Chr t(15;17)","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • fludarabine IV • pivekimab sunirine (PVEK) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-03"},{"id":"5cbe18a7-53bc-4741-8463-14864cc423d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06013423","created_at":"2023-08-28T14:08:26.842Z","updated_at":"2025-02-25T17:32:18.916Z","phase":"Phase 2","brief_title":"Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases","source_id_and_acronym":"NCT06013423","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/23/2024","start_date":" 07/23/2024","primary_txt":" Primary completion: 10/31/2031","primary_completion_date":" 10/31/2031","study_txt":" Completion: 10/31/2032","study_completion_date":" 10/31/2032","last_update_posted":"2025-01-31"},{"id":"1acb7aaf-3833-4bea-94c7-39bf5affa991","acronym":"","url":"https://clinicaltrials.gov/study/NCT06727383","created_at":"2025-02-26T10:10:12.911Z","updated_at":"2025-02-26T10:10:12.911Z","phase":"","brief_title":"CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy Donors","source_id_and_acronym":"NCT06727383","lead_sponsor":"European Institute of Oncology","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/21/2022","start_date":" 12/21/2022","primary_txt":" Primary completion: 12/21/2025","primary_completion_date":" 12/21/2025","study_txt":" Completion: 12/21/2025","study_completion_date":" 12/21/2025","last_update_posted":"2024-12-10"},{"id":"1f02bb00-f1cc-41ae-861d-71bd39144975","acronym":"VYP","url":"https://clinicaltrials.gov/study/NCT06715267","created_at":"2025-02-26T10:35:18.326Z","updated_at":"2025-02-26T10:35:18.326Z","phase":"","brief_title":"Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)","source_id_and_acronym":"NCT06715267 - VYP","lead_sponsor":"University Hospital, Brest","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" CALR mutation","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CALR mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 04/01/2038","primary_completion_date":" 04/01/2038","study_txt":" Completion: 04/01/2038","study_completion_date":" 04/01/2038","last_update_posted":"2024-12-04"},{"id":"54b0572b-d8fb-48d8-acfb-e6927b1cd7aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03912064","created_at":"2021-01-18T19:15:12.856Z","updated_at":"2024-07-02T16:34:27.453Z","phase":"Phase 1","brief_title":"A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT","source_id_and_acronym":"NCT03912064","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL2RA • ISG20","pipe":"","alterations":" ","tags":["IL2RA • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • CD25hi Treg depleted DLI"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/10/2019","start_date":" 07/10/2019","primary_txt":" Primary completion: 05/24/2024","primary_completion_date":" 05/24/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-11"},{"id":"fe8da34f-8155-4e53-a434-b93819c389c5","acronym":"OPTIMIZE","url":"https://clinicaltrials.gov/study/NCT06001385","created_at":"2023-08-21T14:08:42.896Z","updated_at":"2024-07-02T16:34:27.204Z","phase":"Phase 2","brief_title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","source_id_and_acronym":"NCT06001385 - OPTIMIZE","lead_sponsor":"Center for International Blood and Marrow Transplant Research","biomarkers":" HLA-DRB1 • HLA-B • HLA-DPB1 • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-DPB1 • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 12/08/2023","start_date":" 12/08/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-06-11"},{"id":"75104445-162f-444f-84ea-8038034ab832","acronym":"","url":"https://clinicaltrials.gov/study/NCT02727803","created_at":"2021-01-18T13:21:10.406Z","updated_at":"2024-07-02T16:34:36.895Z","phase":"Phase 2","brief_title":"Personalized NK Cell Therapy in CBT","source_id_and_acronym":"NCT02727803","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • BCL2","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • busulfan • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/19/2016","start_date":" 05/19/2016","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-06-10"},{"id":"67ee693c-6b97-4b0f-b34b-6654a4861bbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04603001","created_at":"2021-01-19T20:30:51.296Z","updated_at":"2024-07-02T16:34:58.765Z","phase":"Phase 1","brief_title":"Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT04603001","lead_sponsor":"Eli Lilly and Company","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • LY3410738"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 07/03/2023","primary_completion_date":" 07/03/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"cc779273-45ab-45c8-b571-03dd1632ce79","acronym":"GLB-001-02","url":"https://clinicaltrials.gov/study/NCT06378437","created_at":"2024-04-22T23:49:35.454Z","updated_at":"2024-07-02T16:34:59.114Z","phase":"Phase 1","brief_title":"A Study of GLB-001 in Patients With Myeloid Malignancies","source_id_and_acronym":"NCT06378437 - GLB-001-02","lead_sponsor":"Hangzhou GluBio Pharmaceutical Co., Ltd.","biomarkers":" JAK2","pipe":"","alterations":" ","tags":["JAK2"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 05/24/2024","start_date":" 05/24/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-06-04"},{"id":"0586b97f-ca3e-4935-90c4-ce0d935a32d9","acronym":"NCI-2020-05261","url":"https://clinicaltrials.gov/study/NCT04493138","created_at":"2021-01-18T21:35:02.627Z","updated_at":"2024-07-02T16:34:59.952Z","phase":"Phase 1/2","brief_title":"Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations","source_id_and_acronym":"NCT04493138 - NCI-2020-05261","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3 • ASXL1","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation","tags":["TP53 • FLT3 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Vanflyta (quizartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-30"}]